Steroid premedication for taxol

Henrik S. Thomsen (DK) Chairman ,
Fulvio Stacul (IT) Secretary ,
Torsten Almén (SE),
Marie-France Bellin (FR),
Michele Bertolotto (IT),
Georg Bongartz (CH),
Olivier Clement (FR),
Peter Leander (SE),
Gertraud Heinz-Peer (AT),
Sameh K. Morcos (UK),
Peter Reimer (DE),
Aart J. van der Molen (NL),
Judith AW Webb (UK)

References

  1. JEVTANA Prescribing Information. Bridgewater, NJ: sanofi-aventis . LLC; September 2017.
  2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version ). Eur J Cancer . 2009;45(2):228-247.
  3. Data on file. Clinical study report (TROPIC). A randomized, open label multicenter study of XRP6258 at 25 mg/m 2 in combination with prednisone every 3 weeks compared to mitoxantrone in combination with prednisone for the treatment of hormone refractory metastatic prostate cancer previously treated with a Taxotere-containing regimen. Study number EFC6193. Sanofi-aventis. March 18, 2010.
  4. National Comprehensive Cancer Network ® . Clinical Practice Guidelines in Oncology™: Prostate Cancer. V2. 2017

Steroid premedication for taxol

steroid premedication for taxol

Media:

steroid premedication for taxolsteroid premedication for taxolsteroid premedication for taxolsteroid premedication for taxolsteroid premedication for taxol

http://buy-steroids.org